Efficacy of Tafluprost as an Adjunct to Medical Therapy for Residual Glaucoma After Trabeculectomy
Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
A 6-month, parallel-group study of the safety and efficacy of tafluprostin for Chinese
patients with posttrabeculectomy residual primary angle-closure glaucoma or
posttrabeculectomy residual primary open angle glaucoma.